Cambrex announces investment and expansion in Sweden
Cambrex, manufacturer of small molecule active pharmaceutical ingredients (APIs), has announced it is investing in new capacity and continuous flow technology at its Karlskoga facility in Sweden.
“The additional capacity at the site, within our current infrastructure, will enable us to service our existing and future customers more efficiently,” explained Bjarne Sandberg, managing director, Cambrex Karlskoga. “The continuous flow unit builds on our long experience with continuous flow and high energy chemistry and allows for greater production efficiency and flexibility.”
This expansion and investment is part of the company’s strategic campaign to invest in small molecule API manufacturing across its global facilities.
Written by Felicity Thomas
